311 results on '"Schulman, A."'
Search Results
2. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
3. Periprocedural management of direct oral anticoagulants in patients with atrial fibrillation and active cancer
4. Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry
5. Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
6. Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis
7. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism
8. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure
9. ISTH guidelines for antithrombotic treatment in COVID‐19
10. Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
11. Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation
12. Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients
13. Clinical history of cancer‐associated splanchnic vein thrombosis
14. Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors
15. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta‐analysis
16. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa
17. Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study
18. Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
19. Periprocedural Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Active Cancer
20. Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
21. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism
22. Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis
23. Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta‐analysis of randomized controlled trials
24. Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
25. Duration of anticoagulation for venous thromboembolism in pediatric patients: Kids-DOTT trial outcomes at 2 years
26. Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study
27. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure
28. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings
29. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis
30. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post‐thrombotic syndrome
31. Real‐world variability in dabigatran levels in patients with atrial fibrillation
32. The risk of major bleeding in patients with Factor V Leiden or Prothrombin G20210A gene mutation while on extended anticoagulant treatment for VTE
33. Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial
34. Definition of haemostatic effectiveness in interventions used to treat major bleeding
35. Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach
36. Adherence to anticoagulant treatment with dabigatran in a real‐world setting
37. Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis
38. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH
39. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban
40. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy
41. Anticoagulant therapy for splanchnic vein thrombosis
42. Fondaparinux treatment of acute heparin‐induced thrombocytopenia confirmed by the serotonin‐release assay: a 30‐month, 16‐patient case series
43. Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH
44. Direct and indirect costs of management of long‐term warfarin therapy in Canada
45. Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding
46. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
47. Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study
48. Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study
49. Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding
50. The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.